Peel back peptideprivatelabel
I came to a copper-peptide paper expecting a peptide result. The measurements counted copper. That small distinction opened a much larger question about what a name lets us assume.
Copper in the receiver
Hostynek and colleagues measured copper crossing prepared human skin outside the body in 2011. They applied it as GHK-Cu, a peptide holding a copper ion. They quantified copper that crossed dermatomed skin and copper left as a dermal depot over 48 hours.
The element gets the numerical credit. My first instinct credited the peptide alone; the reported quantities gave copper the credit. A copper measurement can establish copper delivery. Following an intact peptide to another tissue would call for its own measurement.
Private label suggests a new name laid over existing contents. That is a useful place to begin with these peptides: lift the name and look at the material underneath. The copper, the peptide and the preparation can each change the question being asked.
The ingredient file
GHK-Cu contains the tripeptide glycine-histidine-lysine and copper. The skin-regeneration review describes the copper complex and the broader GHK story; a controlled hair trial tested GHK combined with 5-aminolevulinic acid. Those preparations deserve their full names.
TB-500 is a short synthetic fragment of thymosin β4. The human intravenous safety study used the full-length protein, as did the rat stroke experiment. A family resemblance is an invitation to investigate the fragment. That fragment has yet to earn the parent's results.
BPC-157 has a gastric name and a synthetic identity. Its animal work ranges from ulcer healing in rats to recovery after a rat Achilles tendon was cut. Here the ingredient stays recognisable while the tissue and the size of the claim change.
Credit for the preparation
Missing ingredients irritate me. The experiments get more interesting when the preparations remain visible. The combination hair trial is an experiment on a combination. The human-skin experiment reports copper delivery. The thymosin β4 trial tells us about the protein given to its volunteers.
A single league table of “best peptides” would flatten all that work. A small topical study, a rat injury model and an infusion safety study have different jobs. The comparison puts the preparations beside their actual measurements.
The broad caution is substantial: a 2026 sports-medicine review describes favourable animal findings alongside scarce rigorous human safety data and potential for serious harm among unapproved peptides. A recognisable ingredient name gives no exemption from those gaps.
The nerve claim
Nerve repair was the question that brought these three names together here. Within this site's source list, the BPC-157 neural entry is a review of rodent brain-gut work; the thymosin β4 result is neurological improvement after an experimental stroke in rats. The GHK-Cu entries concern skin, hair and gene expression.
For human nerve repair, I see a question still awaiting a clinical answer. None of these entries reports a human peripheral nerve regenerating. Tendon, skin and brain findings each deserve examination on their own terms, with the molecule still attached.